Incyte Past Earnings Performance
Past criteria checks 5/6
Incyte has been growing earnings at an average annual rate of 25.1%, while the Biotechs industry saw earnings growing at 15.9% annually. Revenues have been growing at an average rate of 13.2% per year. Incyte's return on equity is 13.8%, and it has net margins of 19.8%.
Key information
25.1%
Earnings growth rate
24.4%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 13.2% |
Return on equity | 13.8% |
Net Margin | 19.8% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Incyte: The Worst Has Been Avoided
Jun 16It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year
Jun 06We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings
May 07Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)
May 03Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)
Apr 26Incyte: A Potential GARP Superstar
Feb 27Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today
Feb 02Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today
Oct 31Knight's affiliate files for Brazilian approval of cancer drug tafasitamab
Oct 07Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart
Sep 29Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia
Sep 15Incyte wins approval of Pemazyre for rare blood cancer
Aug 26Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6%
Aug 02With EPS Growth And More, Incyte (NASDAQ:INCY) Makes An Interesting Case
Jul 27Incyte Corp. Should Move Higher (Technical Analysis)
Jul 18Incyte: Growth Drivers Are Coming
Jun 17Incyte Is A Buy As Ruxolitinib Ramps Revenue And Pipeline Matures
Apr 14Incyte: All Atention On Opzelura
Mar 21Incyte: Still Has Room To Grow
Jan 24Incyte: The Right Time To Buy The Stock
Dec 28Revenue & Expenses Breakdown
How Incyte makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 3,768 | 745 | 1,143 | 0 |
31 Dec 23 | 3,696 | 598 | 1,159 | 0 |
30 Sep 23 | 3,609 | 425 | 1,138 | 0 |
30 Jun 23 | 3,513 | 366 | 1,136 | 0 |
31 Mar 23 | 3,470 | 324 | 1,105 | 0 |
31 Dec 22 | 3,395 | 341 | 999 | 0 |
30 Sep 22 | 3,331 | 876 | 954 | 0 |
30 Jun 22 | 3,320 | 945 | 879 | 0 |
31 Mar 22 | 3,115 | 933 | 796 | 0 |
31 Dec 21 | 2,986 | 949 | 741 | 0 |
30 Sep 21 | 2,913 | 535 | 682 | 0 |
30 Jun 21 | 2,721 | 338 | 612 | 0 |
31 Mar 21 | 2,703 | 478 | 561 | 0 |
31 Dec 20 | 2,667 | -296 | 518 | 0 |
30 Sep 20 | 2,457 | -335 | 487 | 0 |
30 Jun 20 | 2,388 | -191 | 469 | 0 |
31 Mar 20 | 2,229 | -376 | 457 | 0 |
31 Dec 19 | 2,159 | 447 | 469 | 0 |
30 Sep 19 | 2,108 | 405 | 441 | 0 |
30 Jun 19 | 2,006 | 306 | 435 | 0 |
31 Mar 19 | 1,997 | 253 | 437 | 0 |
31 Dec 18 | 1,882 | 109 | 435 | 0 |
30 Sep 18 | 1,798 | -109 | 424 | 0 |
30 Jun 18 | 1,729 | -102 | 419 | 0 |
31 Mar 18 | 1,534 | -167 | 401 | 0 |
31 Dec 17 | 1,536 | -313 | 367 | 0 |
30 Sep 17 | 1,419 | -155 | 363 | 0 |
30 Jun 17 | 1,306 | -154 | 348 | 0 |
31 Mar 17 | 1,226 | -107 | 324 | 0 |
31 Dec 16 | 1,106 | 104 | 302 | 0 |
30 Sep 16 | 1,023 | 151 | 260 | 0 |
30 Jun 16 | 941 | 74 | 231 | 0 |
31 Mar 16 | 858 | 49 | 216 | 0 |
31 Dec 15 | 754 | 7 | 197 | 0 |
30 Sep 15 | 634 | -86 | 193 | 0 |
30 Jun 15 | 644 | 13 | 184 | 0 |
31 Mar 15 | 581 | -33 | 174 | 0 |
31 Dec 14 | 511 | -48 | 166 | 0 |
30 Sep 14 | 485 | -54 | 155 | 0 |
30 Jun 14 | 372 | -136 | 142 | 0 |
31 Mar 14 | 374 | -101 | 125 | 0 |
31 Dec 13 | 355 | -83 | 110 | 0 |
30 Sep 13 | 372 | -21 | 96 | 0 |
Quality Earnings: INCY has high quality earnings.
Growing Profit Margin: INCY's current net profit margins (19.8%) are higher than last year (9.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INCY's earnings have grown significantly by 25.1% per year over the past 5 years.
Accelerating Growth: INCY's earnings growth over the past year (129.8%) exceeds its 5-year average (25.1% per year).
Earnings vs Industry: INCY earnings growth over the past year (129.8%) exceeded the Biotechs industry -14.4%.
Return on Equity
High ROE: INCY's Return on Equity (13.8%) is considered low.